Development of resident memory T cells in the synovium

滑膜中常驻记忆 T 细胞的发育

基本信息

  • 批准号:
    10601115
  • 负责人:
  • 金额:
    $ 17.33万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-04 至 2027-03-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) are chronic autoimmune diseases of the joint punctuated by periodic arthritis flares. Clinicians have long recognized that each affected person develops an individual pattern of affected joints, and that this pattern remains stable over time through disease remission and flares. We recently identified the presence of synovial resident memory T cells (TRM) in arthritic joints and showed that they mediate arthritis flares. Correspondingly, depleting these cells ameliorates disease recurrence, indicating that TRM can be targeted as a novel approach in arthritis therapy. The long-term objective of the proposal is to define the mediators of TRM development and maintenance in the synovium and determine if these pathways can be therapeutically targeted to treat arthritis. The specific aims of this proposal utilize 2 complementary approaches in mice and human studies to identify the mediators of synovial TRM development. Aim 1 utilizes a mouse model of inflammatory arthritis developed by the PI to define the lineage and differentiation process of synovial TRM. Aim 2 utilizes a human synovial organoid system to interrogate the impact of the synovial microenvironment, namely synovial stromal cells, on TRM formation and survival. We expect that these studies will identify critical mediators of TRM development, which may represent novel therapeutic targets for inflammatory arthritis. The candidate is an M.D./Ph.D. pediatric rheumatologist at Boston Children’s Hospital. This proposal builds upon her foundational knowledge of immunology to extend her skillset into antibody-coupled single cell sequencing, bioinformatics, organoid models of human synovium, and CRISPR gene targeting. The proposal includes a comprehensive mentoring and didactic plan that will allow her to successfully learn new skills and gain expertise in each of these important areas. The primary mentor, Dr. Peter Nigrovic, is a rheumatologist and expert in the pathophysiology of inflammatory arthritis. The candidate has assembled a K08 advisory committee consisting of Dr. Michael Brenner, Dr. Rachael Clark, and Dr. Soumya Raychaudhuri, who each have specific expertise in various aspects of this proposal such as analysis of single-cell sequencing data, 3D models of human synovium, and expertise in TRM biology in human disease. The candidate is committed to a career in translational research with the goal of becoming an independent lab-based investigator focusing on local mechanisms to autoimmune disorders. The proposed studies, training plan, and exceptional environment at Boston Children’s Hospital, Brigham and Women’s Hospital and Harvard Medical School will enable her to successfully transition to an independent PI and leader in this field.
项目摘要/摘要 类风湿关节炎(RA)和青少年特发性关节炎(JIA)是关节的慢性自身免疫性疾病 周期性关节炎耀斑点击。临床医生长期以来已经认识到每个受影响的人都会发展 受影响关节的个体模式,并且通过疾病缓解和 耀斑。我们最近确定了滑膜居民记忆T细胞(TRM)的存在,并显示 它们介导关节炎的耀斑。相应地,耗尽这些细胞可改善疾病复发, 表明TRM可以作为关节炎治疗的新方法。长期目标 建议是定义Syromovium中TRM开发和维护的介体,并确定这些是否是否 可以热靶向治疗关节炎的途径。 该提案的具体目的利用小鼠和人类研究中的两种完整方法来确定 滑膜TRM开发的介体。 AIM 1利用了由炎症性关节炎的小鼠模型 PI定义滑膜TRM的谱系和分化过程。 AIM 2利用人类滑膜器官 询问滑膜微环境(即滑膜基质细胞)对TRM的影响的系统 形成和生存。我们希望这些研究将确定TRM开发的关键调解人,这 可能代表炎性关节炎的新型治疗靶标。 候选人是M.D./ph.d。波士顿儿童医院的小儿风湿病学家。该提议建立在 她对免疫学的基本知识将其技能扩展到抗体耦合的单细胞测序中, 生物信息学,人类滑膜的器官模型和CRISPR基因靶向。该提案包括一个 全面的指导和教学计划,这将使她能够成功学习新技能并获得专业知识 在这些重要领域中的每个领域。主要导师彼得·尼格罗维奇(Peter Nigrovic)博士是风湿病学家和专家 炎症性关节炎的病理生理。候选人已组建一个K08咨询委员会,该委员会由 Michael Brenner博士,Rachael Clark博士和Soumya Raychaudhuri博士,他们在 该建议的各个方面,例如分析单细胞测序数据,人类滑膜的3D模型, 和人类疾病中TRM生物学的专业知识。候选人致力于转化研究的职业 目的是成为一名基于实验室的独立研究者,专注于自身免疫的本地机制 疾病。波士顿儿童医院提议的研究,培训计划和特殊环境, Brigham and妇女医院以及哈佛医学院将使她成功过渡到 独立的PI和该领域的领导者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Margaret Chang其他文献

Margaret Chang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Margaret Chang', 18)}}的其他基金

Development of resident memory T cells in the synovium
滑膜中常驻记忆 T 细胞的发育
  • 批准号:
    10427963
  • 财政年份:
    2022
  • 资助金额:
    $ 17.33万
  • 项目类别:
Galectin-1's effects on dendritic cell function.
Galectin-1 对树突状细胞功能的影响。
  • 批准号:
    7676449
  • 财政年份:
    2009
  • 资助金额:
    $ 17.33万
  • 项目类别:
Galectin-1's effects on dendritic cell function.
Galectin-1 对树突状细胞功能的影响。
  • 批准号:
    8323368
  • 财政年份:
    2009
  • 资助金额:
    $ 17.33万
  • 项目类别:
Galectin-1's effects on dendritic cell function.
Galectin-1 对树突状细胞功能的影响。
  • 批准号:
    8127678
  • 财政年份:
    2009
  • 资助金额:
    $ 17.33万
  • 项目类别:

相似海外基金

Lung resident Treg suppression of Th2 resident memory T cells in allergic asthma
过敏性哮喘中肺常驻 Treg 对 Th2 常驻记忆 T 细胞的抑制
  • 批准号:
    10664599
  • 财政年份:
    2023
  • 资助金额:
    $ 17.33万
  • 项目类别:
Democratizing CAR T cell therapy by in situ programming of virus-specific T cells
通过病毒特异性 T 细胞的原位编程使 CAR T 细胞疗法大众化
  • 批准号:
    10739646
  • 财政年份:
    2023
  • 资助金额:
    $ 17.33万
  • 项目类别:
Lung epithelial cell reprogramming by CD4 T cells
CD4 T 细胞对肺上皮细胞进行重编程
  • 批准号:
    10747632
  • 财政年份:
    2023
  • 资助金额:
    $ 17.33万
  • 项目类别:
Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemia
项目 4:现成的工程化脐带血自然杀伤细胞,用于治疗急性淋巴细胞白血病
  • 批准号:
    10931069
  • 财政年份:
    2023
  • 资助金额:
    $ 17.33万
  • 项目类别:
Pathogenic T cells in discoid lupus erythematosus
盘状红斑狼疮中的致病性 T 细胞
  • 批准号:
    10664134
  • 财政年份:
    2023
  • 资助金额:
    $ 17.33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了